TickerFacts.

GRAIL, Inc. (GRAL): Revenue

Annual figures by period end, from SEC filings.

$147.17M
Year ended 2025-12-31
$165.26M
Trailing 12 months to 2026-06-30
+38.4%
3-year compound annual growth
2023-01-01: $55.55M2023-12-31: $93.11M2024-12-31: $125.59M2025-12-31: $147.17M$147.17M
2023-01-01 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$147.17M+17.2%2026-03-12, From 2025-01-01
2024-12-31$125.59M+34.9%2026-03-12, From 2024-01-01
2023-12-31$93.11Mn/a2026-03-12, From 2023-01-01
2023-01-01, Fiscal 2022$55.55Mn/a2025-03-05, From 2022-01-03

Revenue at similar companies

Companies with the same SEC industry code (Services-Medical Laboratories), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
GRAIL, Inc. (GRAL)2025-12-31$147.17M+17.2%
Biodesix Inc (BDSX)2025-12-31$88.50M+24.1%
BillionToOne, Inc. (BLLN)2025-12-31$305.11M+100.0%
Personalis, Inc. (PSNL)2025-12-31$69.65M-17.7%
Fulgent Genetics, Inc. (FLGT)2025-12-31$322.67M+13.8%
Exagen Inc. (XGN)2025-12-31$66.58M+19.7%
Castle Biosciences Inc (CSTL)2025-12-31$344.23M+3.7%
CareDx, Inc. (CDNA)2025-12-31$379.81M+13.8%
Veracyte, Inc. (VCYT)2025-12-31$517.14M+16.0%

Compare GRAL, BDSX, BLLN, PSNL side by side · Screen every company in Services-Medical Laboratories ↗